Read by QxMD icon Read


(no author information available yet)
[This corrects the article on p. 1911 in vol. 10, PMID: 25336957.].
2014: Neuropsychiatric Disease and Treatment
Gregory M Asnis, Margaret A Henderson
The EMSAM patch is a unique monoamine oxidase inhibitor (MAOI) being the only antidepressant utilizing a transdermal delivery system. This was welcomed by clinicians who hoped that EMSAM would be better tolerated than oral MAOIs and non-MAOI antidepressants, as well as being effective for treatment in a wide spectrum of depressed patients including atypical depression, bipolar depression, and refractory depression. Unfortunately, the clinical use of EMSAM has been underutilized and its potential usefulness overlooked...
2014: Neuropsychiatric Disease and Treatment
Joanna S Fowler, Jean Logan, Nora D Volkow, Elena Shumay, Fred McCall-Perez, Millard Jayne, Gene-Jack Wang, David L Alexoff, Karen Apelskog-Torres, Barbara Hubbard, Pauline Carter, Payton King, Stanley Fahn, Michelle Gilmor, Frank Telang, Colleen Shea, Youwen Xu, Lisa Muench
Selegiline (L-deprenyl) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at the conventional dose (10 mg/day oral) that is used in the treatment of Parkinson's disease. However, controlled studies have demonstrated antidepressant activity for high doses of oral selegiline and for transdermal selegiline suggesting that when plasma levels of selegiline are elevated, brain MAO-A might also be inhibited. Zydis selegiline (Zelapar) is an orally disintegrating formulation of selegiline, which is absorbed through the buccal mucosa producing higher plasma levels of selegiline and reduced amphetamine metabolites compared with equal doses of conventional selegiline...
February 2015: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
Melissa P DelBello, Thomas J Hochadel, Kimberly Blanchard Portland, Albert J Azzaro, Alain Katic, Arif Khan, Graham Emslie
OBJECTIVE: A randomized, double-blind, placebo-controlled flexible-dose, parallel group trial was conducted at 26 clinical investigational sites in the United States to examine the safety and efficacy of the selegiline transdermal system (STS) (EMSAM®) in adolescents (ages 12-17 years) meeting American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) criteria for moderate to severe major depressive disorder (MDD) without psychotic features...
August 2014: Journal of Child and Adolescent Psychopharmacology
Elisa F Cascade, Amir H Kalali, Sheldon H Preskorn
We investigated the use of EMSAM in the first year post-launch in the US-April of 2006 through March of 2007. According to our data, EMSAM represents <0.1 percent of total prescriptions for antidepressants in the US and is prescribed most often by psychiatrists (83%of prescriptions). The impact of the product on the MAO inhibitor class, however, has been significant. We found that EMSAM now represents 30 percent of all MAO inhibitor use and has been a catalyst for growth in the overall MAO inhibitor class...
June 2007: Psychiatry
Lois Jessen, Lawrence J Kovalick, Albert J Azzaro
Although monoamine oxidase inhibitors (MAOIs) at one time represented the mainstay of therapy for major depressive disorder (MDD), the risk of acute hypertensive reactions following the ingestion of tyramine-rich foods and the consequent need to restrict dietary tyramine represent a barrier to their use. In this article, we present an overview of the efficacy and safety of a transdermal formulation of the MAOI selegiline for the treatment of MDD. Transdermal delivery of selegiline at the effective dose of 6 mg every 24 hours eliminates the need for a tyramine-restricted diet...
April 2008: P & T: a Peer-reviewed Journal for Formulary Management
Kelly C Lee, Jack J Chen
Non-selective inhibition of monoamine oxidase (MAO) enzymes (ie, isoforms A and B) in the brain are associated with clinically significant antidepressant effects. In the US, the selegiline transdermal system (STS; EMSAM) is the first antidepressant transdermal delivery system to receive Food and Drug Administration (FDA) approved labeling for the treatment of major depressive disorder (MDD). Currently, the use of orally administered MAO inhibitor antidepressants (eg, phenelzine, tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the "cheese reaction") when combined with dietary tyramine...
2007: Neuropsychiatric Disease and Treatment
Chi-Un Pae, Hyun-Kook Lim, Changsu Han, Ajwani Neena, Chul Lee, Ashwin A Patkar
Many monoamine oxidase inhibitors (MAOIs) have been used to treat major depressive disorder (MDD). However, the prescription of MAOIs has decreased considerably as a result of side effects such as tyramine-induced hypertensive crisis, which is also known as the 'Cheese Effect'. The drug delivery system itself can affect the bioavailability of certain drugs, which might influence the efficacy and tolerability of medications, as well as improve the compliance and reduce the incidence of recurrence and relapse...
August 15, 2007: Progress in Neuro-psychopharmacology & Biological Psychiatry
(no author information available yet)
No abstract text is available yet for this article.
May 22, 2006: Medical Letter on Drugs and Therapeutics
(no author information available yet)
No abstract text is available yet for this article.
2003: Drugs in R&D
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"